Etanercept data
| Total population | ||||
|---|---|---|---|---|
| COBRA (n=81) | COBRA-light (n=81) | RR (95% CI)* | p Value | |
| Etanercept start required, total patients (DAS44 ≥1.6), n (%) | 47 (59) | 61 (75) | 1.67 (1.05 to 2.65) | 0.03 |
| Based on DAS44 ≥1.6 and <2.4, n (%) | 29 (62) | 31 (51) | 1.03 (0.81 to 1.31) | 0.79 |
| Based on DAS44 ≥2.4, n (%) | 18 (38) | 30 (49) | 1.23 (1.00 to 1.51) | 0.04 |
| Actual started, total (DAS44 ≥1.6), n (%) | 27 (57) | 40 (66) | 1.30 (0.82 to 2.08) | 0.04 |
| Based on DAS44 ≥1.6 and <2.4, n (%) | 15 (56) | 18 (45) | 0.88 (0.54 to 1.42) | 0.59 |
| Based on DAS44 ≥2.4, n (%) | 12 (44) | 22 (55) | 1.24 (0.76 to 2.00) | 0.40 |
| Activity at intended start: etanercept actual starters vs non-starters | ||||||
|---|---|---|---|---|---|---|
| COBRA (n=50) | COBRA-light (n=61) | |||||
| Starters (n=27) | Non-starters (n=22) | p Value | Starters (n=40) | Non-starters (n=21) | p Value | |
| DAS44 | 2.44 (0.7) | 2.24 (0.6) | 0.30 | 2.66 (0.9) | 2.05 (0.5) | <0.01 |
| Tender joints | 8.5 (5.9) | 9.3 (11.9) | 0.77 | 9.4 (9.5) | 2.8 (1.6) | <0.01 |
| Swollen joints | 5.0 (4.0) | 4.2 (9.4) | 0.73 | 6.4 (7.5) | 1.6 (1.8) | <0.01 |
| HAQ† | 0.87 (0.7) | 0.69 (0.6) | 0.45 | 0.98 (0.7) | 0.61 (0.6) | 0.10 |
| ESR, mm/h, median (IQR) | 6.0 (3.0–9.0) | 8.5 (4.0–14.0) | 0.10 | 13.0 (3.3 to 22.8) | 18.5 (6.5 to 24.5) | 0.43 |
| CRP, mg/L, median (IQR) | 2.8 (1.8–5.5) | 2.5 (2.0–9.0) | 0.90 | 4.0 (1.0 to 10.0) | 2.8 (1.8 to 5.0) | 0.43 |
| Patient global assessment, by VAS, mm | 41.4 (23.4) | 46.7 (24.0) | 0.45 | 43.3 (25.5) | 28.7 (22.3) | 0.03 |
Data are expressed as mean (SD) unless otherwise stated.
*RR analyses.
†HAQ score was only assessed at week 26.
COBRA, Combinatietherapie Bij Reumatoïde Artritis; CRP, C-reactive protein; DAS44, 44-joint count Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RR, relative risk; VAS, visual analogue scale.